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Abstract
Chronic obstructive pulmonary disease (COPD) is one of the prevalent causes of worldwide 
mortality and encompasses two major clinical phenotypes, i.e., chronic bronchitis (CB) and 
emphysema. The most common cause of COPD is chronic tobacco inhalation. Research focused 
on the chronic bronchitic phenotype of COPD has identified several pathological processes that 
drive disease initiation and progression. For example, the lung’s mucociliary clearance (MCC) 
system performs the critical task of clearing inhaled pathogens and toxic materials from the lung. 
MCC efficiency is dependent on: (i) the ability of apical plasma membrane ion channels such as 
the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial Na+ channel 
(ENaC) to maintain airway hydration; (ii) ciliary beating; and, (iii) appropriate rates of mucin 
secretion. Each of these components is impaired in CB and likely contributes to the mucus stasis/
accumulation seen in CB patients. This review highlights the cellular components responsible for 
maintaining MCC and how this process is disrupted following tobacco exposure and with CB. We 
shall also discuss existing therapeutic strategies for the treatment of chronic bronchitis and how 
components of the MCC can be used as biomarkers for the evaluation of tobacco or tobacco-like-
product exposure.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
worldwide and is projected to become the third leading cause of death by 2030 [1]. COPD is 
characterized by a persistent airflow limitation that is progressive and associated with an 
augmented chronic inflammatory state [2]. COPD occurs after chronic environmental 
exposure to tobacco smoke and/or other noxious particles or gases [2, 3], but may also have 
a genetic component that predisposes certain populations to COPD [4].
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Chronic bronchitis (CB) and emphysema are considered as the two major clinical and 
epidemiological phenotypes of COPD. Production of sputum and cough for at least 3 
months over two consecutive years defines CB, whereas emphysema is defined by the 
“destruction of the gas-exchanging surfaces of the lung” [2]. Most COPD patients exhibit 
symptoms of both emphysema and CB [5]. However, CB is typically the more prevalent 
phenotype [6]. The clinical manifestations of CB (sputum production and a failure of mucus 
transport concomitant with chronic inflammation) are similar to the symptoms reported in 
early cystic fibrosis (CF) lung disease. CF is caused by mutations in the CFTR anion 
channel [7], which lead to reduced airway surface liquid (ASL) volume and subsequent 
mucus dehydration, mucus stasis and recurring airway infections [8–10]. Although the 
causal factors appear different, recent evidence suggests that the acquired dysfunction of 
CFTR-mediated ion transport following chronic tobacco exposure may also contribute to CB 
pathogenesis [11]. Indeed, the mucus hydration status of the airways has both direct and 
indirect effects on pulmonary health [12, 13]. Thus, it has been proposed that the 
pathophysiology of the two diseases, i.e. CF and COPD, share similar initiation and 
progression scenarios, with compromised mucus hydration being common [14, 15]. In this 
review, we shall discuss the pathophysiology of the chronic bronchitis form of COPD (see 
Figure 1), and how this knowledge may generate (i) novel treatment regimens and (ii) 
clinically relevant novel biomarkers of exposure.
Causes of COPD
Mortality in COPD in part reflects pulmonary failure, but may be dominated by 
comorbidities such as cardiovascular disease and lung cancer. Although the principal 
etiological factor for COPD is chronic tobacco smoke exposure, the involvement of genetic, 
epigenetic and host-factors is evident by the fact that only a fraction of smokers develop the 
disease. The CB incidence rate in smokers is typically suggested to be around 25% [16]. 
However, COPD may be underreported, and in the USA, for example, ~12 million adults 
have been diagnosed with the disease, but an equal number of people likely suffer from 
COPD without an official diagnosis. [17]. In addition to tobacco exposure, both indoor and 
outdoor pollution can also cause COPD in non-smokers [18–21]. As such, biomass smoke 
exposure (e.g. smoke from wood burning stoves) and occupational pollutant exposure are 
also considered significant risk factors for COPD [22, 23].
Apart from external etiological factors, the most crucial genetic risk factor for COPD is α1-
anti trypsin deficiency [24]. The α1-anti trypsin protein is coded by the serpin peptidase 
inhibitor, clade A, member 1 (SERPINA1) gene [25]. α1-anti trypsin deficiency is an 
autosomal co-dominant state that leads to reduced levels of α1-anti trypsin in circulating 
blood and corresponding failure to inhibit neutrophil elastase [26]. Even without exposure to 
tobacco smoke, the subsequent uncontrolled neutrophil elastase activity can lead to lung 
damage and early onset COPD [27]. Significant pulmonary destruction is visible by the age 
of 30 in many patients [27], and α1-anti trypsin deficiency-induced lung disease worsens 
upon exposure to environmental toxicants such as tobacco smoke [4, 26, 28, 29].
The airway surface mediates normal mucus clearance and reduced ASL volume, i.e. 
hydration, produces the reduction in mucus clearance. Severe reductions in mucus clearance 
Ghosh et al. Page 2













are associated with increase mucus stasis/mucus adhesion, which lead to the increase in 
inflammation and bacterial infections characteristic of CF and CB [30]. Investigations into 
the pathophysiologic basis of chronic bacterial airways infection typically reveal that 
airways obstruction is the primary cause of this syndrome [31, 32]. Airways obstruction can 
be produced by intraluminal airway tumors and inhalation of foreign bodies. However, the 
most common form of airways infection is associated with the intraluminal obstruction 
produced by mucus adhesion, mucus plaques, and ultimately, mucus plugs [33–35]. For 
example, the pathologic studies of Hogg et al, indicated that this scenario is central to the 
pathogenesis and progression of the CB phenotype of COPD [36, 37].
The mucus clearance component of the lung’s innate defense system
The lung is frequently exposed to inhaled pathogens and pollutants. However, by the time 
that inhaled air reaches the alveolar surfaces, it has been filtered and humidified [38]. These 
functions are largely performed by the innate defense system of the upper respiratory tract 
[38, 39]. Under normal conditions, pulmonary secretions contain soluble anti-microbial 
factors, macrophages, and mucins that each play a role in mediating the initial responses to 
toxic or infective inhalations [40–42]. The surface epithelium of the airways coordinates 
these responses via multiple specialized cell types, including columnar ciliated cells and 
mucous (goblet) cells, along with underlying basal cells. Mucins were secreted by the 
surface epithelial goblet cells in parallel with mucins derived from submucosal glands, 
which in the large airways open onto the airway surface through a series of ducts [43].
Most mucosal surfaces that interface with the outside world are “wet” mucosal surfaces 
[44]. As a general principle, “wetness” is a required characteristic for mechanical clearance, 
e.g., is required for the efficiency of blinking, swallowing, and indeed, mucus clearance 
[45]. Heretofore, it was generally assumed that the major determinants of the efficiency of 
mucus clearance were the actions of cilia and the rate of mucin secretion [46, 47]. Indeed, 
both are important contributors to the overall efficiency of mucus clearance, but evidence 
now suggests that the hydration status of the environment is the dominant variable for the 
efficiency of the mucus clearance process [48]. Under physiologic conditions, the mucus 
layer acts as a reservoir for water, i.e., it can donate or accept added liquid, to maintain 
apposition of the inner surface of the mucus layer with the tips of the cilia [48]. This 
regulation serves to preserve the hydration status of the pericilliary liquid layer (PCL), 
which is required for cell surface lubrication and for efficient ciliary beating. Mucus 
clearance can accelerate above basal rates when liquid is added to the airway lumen, 
consistent with the in vitro studies of human bronchial epithelial cultures (HBECs) with 
confocal and epifluorescence microscopy [48, 49]. When liquid is removed from the ASL in 
an inappropriate fashion, e.g., as in CF and CB [15], the supply of water “donated” from the 
mucus layer to the PCL can be exhausted, and the PCL will become dehydrated and 
collapse. The thickened (concentrated) mucus layer then comes into contact with cell surface 
microvilli, cilia and ultimately adheres (14). As a result of this interaction, mucus clearance 
ceases and the nidus for plaque/plug formation is generated.
Efficient mucus clearance from airway surfaces requires the coordinated activities of a 
“transported layer”, i.e., the mucus layer, a cell surface layer, and cilia [50, 51]. The 
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biophysical requirements for a mucus layer to exhibit efficient clearance are daunting and 
only beginning to be understood. The mucus layer must have viscoelastic properties that 
enable the transfer of energy from ciliary beating to the vectorial movement of mucus 
towards the mouth [45]. The mucus layer must also have properties that will allow it to bind 
and entrap virtually all deposited particles so they may be removed from the pulmonary 
surface, yet not adhere to the cell surface [52]. Finally, the mucus layer must be able to 
adapt to local stresses to maintain its viscoelastic and other properties to provide optimum 
transport [44, 53, 54].
A new concept has emerged as to how the mucus layer is organized to provide these 
functions [55]. High molecular weight, extraordinarily long (0.5–20 μm) mucins (MUC5AC, 
MUC5B) are secreted onto the airway surface to form the mucus layer. However, the 
functional properties of this layer are also provided by interacting globular proteins. Indeed, 
this mucin interactome may provide both cross-links between mucin monomers and serve to 
build complex molecular compartments with their own innate defense activities [56, 57]. In 
parallel, our concept of the cell surface layer, i.e. the PCL, has undergone a dramatic 
evolution within the past several years. The emerging data on the identification of cell 
surface tethered mucins (MUC1, 4, 16) led to the hypothesis that the periciliary environment 
is comprised of a polyelectrolyte gel rather than a liquid layer [57]. This concept is 
important because it predicts that the distribution of water between the gels on the airway 
surface will in part reflect the relative concentration of mucus in each compartment. The 
“water drawing” power of each gel can be measured in terms of its osmotic modulus or 
pressure [58]. Importantly, mucin concentrations in diseased lungs cannot accurately be 
measured using Western blot-based approaches and instead must be measured by physic-
chemical techniques. As a case in point, many of the epitopes in the mucins found in CF 
mucus that are recognized by antibodies are degraded in the highly proteolytic environment 
of the CF lung, yielding erroneous results by Western blot. However, both mass 
spectrometry analysis and refractometry measurements of the void volume indicated that CF 
mucin levels are increased relative to normal mucinlevels [58].
Goblet cells and mucins of the conducting airways
Chronic mucus hypersecretion has been identified as a potential risk factor for mortality in 
COPD because of the associated accelerated loss of lung function with this exposure [59]. 
One of the characteristic features of obstructive lung diseases is mucus hypersecretion that is 
driven in part by glandular hypertrophy but also by goblet cell hyperplasia and metaplasia, 
especially in the glandless small airways. As such, goblet cells contribute to the 
hypersecretion of mucins in CB airways [60]. The replacement of ciliated epithelial cells by 
goblet cells is complex and is in part driven by inhibition of apoptosis by EGFR, and/or 
IL-13-dependent activation of MEK/ERK [61–63]. The increase in mucin secretion in CB 
lungs may provide a protective coat of mucus that line the airways to limit toxicant 
exposure. Accordingly, while mucus obstruction is deleterious in the long term, in the short 
term, it may protect the airways against tobacco exposure by acting as a barrier to tobacco 
smoke diffusion. Mucin knock out mice exist (MUC5b−/−) and exhibit increased 
susceptibility to infection [64], but the effects of tobacco exposure on these mice has not 
been established.
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Often with a molecular mass over 500 kDa, mucins are 50–80% O-linked oligosaccharides 
by weight [65]. Mucins may be divided into two major groups, (i) membrane bound and (ii) 
secreted. Secreted mucins are classified as gel-forming and non-gel forming types. The 
secretion of mucins occurs through both the constitutive and regulated secretory pathways 
[66]. As part of the constitutive pathway, mucin-containing vesicles from the trans-Golgi 
network are released extracellularly, creating a “baseline activity” of mucin secretion that is 
Ca2+-independent. [67]. Tethered mucins are typically trafficked to the cell surface by a 
constitutive pathway [68, 69]. In the regulated pathway, mucin-containing vesicles are 
transported from donor to storage compartments. For example, after synthesis in the 
endoplasmic reticulum, vesicles carrying mucins are transferred to the cis-Golgi for core 
glycosylation. They then undergo a maturation process in the Golgi and pass through the 
trans-Golgi to storage granules [66]. The mucin containing granules are trafficked towards 
the apical plasma membrane for secretion in a Rab GTPase-dependent fashion [66]. Studies 
with the SPOC1 rat goblet cell line demonstrated that increases in intracellular Ca2+ elicited 
by purinergic receptor stimulation triggered mucin secretion [70]. Further studies with the 
protein kinase C activator Phorbol 12-myristate 13-acetate and the Ca2+ ionophore 
ionomycin in goblet cell mucin secretion demonstrated the involvement of Ca2+ and protein 
kinase C in this process [71].
Upon secretion, the data of Verdugo et al. demonstrated that mucins “exploded” out of 
vesicles like a “jack in the box”. The mechanism for this phenomenon reflects the fact that a 
pore is formed between the secretory granule and the plasma membrane, extracellular Na+ 
exchanges for Ca2+ in the granule, and mucins are osmotically expelled from the granule 
onto airway surfaces. A key aspect of this mechanism is that mucins contain negative 
charges that would normally repel other mucins when they are densely packed. However, 
the Ca2+ and H+ in the granules shield mucin negative charges and allow the mucins to 
remain closely packed. This exchange of Ca2+ and H+ for Na+, causes mucins to expand 
~600 times when they are secreted [72]. Consequently, mucins are secreted ‘dry’ with water 
being supplied by CFTR-mediated Cl− secretion via the ciliated cells [73].
Ciliated cells of the conducting airways
The motive force for mucociliary clearance in the airways is provided by the ciliated cells of 
the respiratory tract. There are typically ~200 cilia per cell and their beating at ~10–15 Hz 
propels mucus and trapped pathogens/particles towards the oropharynx where it is expelled 
or swallowed in order to maintain pulmonary sterility [74]. Ciliary epithelia are polarized, 
with cilia being exclusively located at the apical plasma membrane. Ciliary orientation is 
determined by planar cell polarity proteins and their associated signaling pathways and is 
initiated before ciliogenesis[See [75] for a comprehensive review]. In airway epithelia, 
ciliogenesis is under the control of the forkhead box J1 (FoxJ1) transcription factor [76] and 
knockout of this gene in a mouse model prevents ciliogenesis [77]. More than 600 proteins 
have been identified in cilia [78]. Motile cilia typically exhibit the “9+2” arrangement where 
two singlet microtubules are surrounded by nine doublet microtubules along with several 
other components such as dynein arms, radial spokes and other proteins that are required for 
proper ciliary assembly and beating [79].
Ghosh et al. Page 5













Ciliary beating is typically under the control of second messengers similar to those that 
increase mucin secretion, and elevations in Ca2+, cAMP and cGMP have been shown to 
increase beat frequency [80–84] [85–88]. This increase may be triggered by Gs-linked 
GPCRs such as P2Y2-R and adenosine receptors [89]. cAMP/PKA-dependent regulation of 
ciliary beating is best understood and PKA and A-kinase anchoring proteins (AKAPs) have 
been found in cilia [90]. In contrast, while Ca2+ is thought to directly increase ciliary 
beating, in a PKC-independent fashion, PKC activation is thought to slow ciliary beating 
[91].
Role of ion channels in airway mucus hydration
As noted above, in addition to ciliary beating, a major element that must be maintained for 
efficient mucociliarly clearance is the hydration status of the mucus [12]. The predominant 
experimental evidence has identified two airway epithelial major ion transport pathways 
which play crucial roles in determining hydration of airway surfaces, namely anion secretion 
and cation absorption. These opposing forces are balanced by the surface epithelium to 
osmotically regulate airway hydration [92]. Na+ absorption across the apical plasma 
membrane is mediated by the epithelial Na+ channel (ENaC) [93, 94]. Cl− secretion can 
occur either by CFTR, or by the Ca2+ activated Cl− channel (CaCC, imcluding Anoctamin 1/
TMEM16A) [95, 96]. Ciliated cells are known to co-express Anoctamin 1, CFTR and ENaC 
[97], suggesting that they can both hydrate the ASL and move mucus to maintain lung 
sterility.
CFTR is an anion channel and adenine nucleotide binding cassette (ABC) protein, belonging 
to the ABC transporter subfamily [98]. CFTR is unique amongst ABC proteins in two ways. 
First, although CFTR has structural similarity to ABC proteins and has 12 transmembrane-
spanning domains and two nucleotide-binding domains, it does not act as a transporter 
protein, but rather functions as an anion channel [99–101]. Second, CFTR has an extra 
intracellular segment known as the regulatory domain or R-domain, which is not a feature of 
other ABC proteins. The R-domain can be extensively phosphorylated which serves to gate 
the channel [100, 102]. Typically, ABC proteins bind ATP and use the energy to drive the 
transport of various molecules across cell membranes [103]. In CFTR, the interactions of 
ATP with nucleotide binding domains control opening and closing of the channel pore rather 
than driving solute transport [98]. Disease-causing CFTR mutations have been extensively 
studied [7]. For example, the F508 CFTR mutation, where phenylalanine at position 508 is 
deleted, induces CFTR retention in the endoplasmic reticulum, decreases CFTR open 
probability, and reduces residence time in the plasma membrane.
ENaC is a heterotrimer consisting of α, β and γ-subunits [104, 105]. While this is the subunit 
combination that is typically found in the lung, in other tissues, ENaC may be substituted by 
a δ-subunit [84–86]. The α- and γ-subunits must be proteolytically cleaved for ENaC to be 
activated and to conduct Na+ [106, 107]. The function of the β-subunit is likely regulatory in 
nature [87]. α and γ ENaC subunits can also be ubiquitination on their N-termin by the E3 
ubiquitin ligase Nedd4.2, which plays a significant role in determining the channel half-life 
[108]. Interestingy, knockdown of NEDD4.2 (NEDD4L) in mice leads to upregulation of 
ENaC and the development of significant lung pathology [109].
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When CFTR is activated, Cl− and HCO3− are secreted into the airway lumen, with Na+ and 
H2O following passively through the paracelluar pathway. This coordinated response results 
in an isotonic increase in ASL height/volume [12, 110–112]. Conversely, when ENaC is 
activated, Na+ moves from the airway lumen into the blood and Cl−/H2O follow 
paracellularly in the same direction, decreasing ASL volume [113]. Cl− is the most abundant 
anion in the ASL (~120 mM) and provides the driving force for the osmotically induced 
changes in ASL volume. In contrast, HCO3− is present at smaller concentrations (~30 mM) 
and likely has proportionately has effect on ASL volume [114]. In addition, HCO3− likely 
plays an important role in buffering ASL pH [72, 115]
Normal airway epithelia can sense ASL volume and adjust ion transport rates accordingly, 
using several feedback systems including: (i) soluble volume sensors encoded in the ASL, 
such as short palate lung and nasal epithelial clone 1 (SPLUNC1) ATP, and adenosine to 
regulate ENaC and CFTR [116, 117], and (ii) ciliary beating to directly sense ASL/mucus 
hydration and response with control of ATP release rates [118]. These processes have been 
extensively reviewed elsewhere [83, 89, 119, 120]. The optimal height of the periciliary 
layer has been determined to be ~7 μm for normal ASL. This height reflects a well hydrated 
PCL layer, which is optimal for mucus clearance since it provides a low frictional 
environment that allows cilia to beat and mucus to flow. A decreased PCL height due to 
CFTR deficiency in CF and COPD airways has been associated with reduced mucus 
clearance and impaired lung innate defense [15, 49, 121].
Whilst ENaC must be cleaved to be activated, it can then be inhibited via several different 
routes. ENaC’s intracellular N-termini interact with PIP2 to open the gate of the channel. 
Purine nucleotides, such as ATP, acting through Gq-linked P2Y2 receptors, are able to 
deplete the intracellular face of the plasma membrane of PIP2, which leads to a decrease in 
ENaC’s open probability[122–124]. ENaC’s open probability can also be affected by 
cAMP/PKA-induced phosphorylation, which in the airways can be mediated by 2 adrenergic 
receptors or A2BR purinergic receptors, both of which are Gs-linked and raise cAMP [95]. 
The number of ENaC subunits at the plasma membrane is also regulated by short palate lung 
and nasal epithelial clone 1 (SPLUNC1), a 25 kDa protein that is secreted into the ASL by 
the underlying epithelia. SPLUNC1 binds directly to β-ENaC [125], which causes ENaC to 
be internalized [126]. An 18 amino acid long region of the protein, termed the S18 region, 
has also been shown to inhibit ENaC and to slow ASL volume absorption [125]. SPLUNC1-
dependent regulation of ASL volume is defective in CF airways [127]. That is, CF ASL is 
mildly acidic due to the lack of HCO3− secretion through CFTR (~pH 7.0 in normal ASL; 
~pH 6.5 in CF ASL)[128] and SPLUNC1 is a pH-sensitive protein that fails to regulate 
ENaC at ≤ pH 6.5 [127, 129]. SPLUNC1 expression may be increased in COPD airways 
[130]. However, the possible effect of CFTR diminution on ASL pH and subsequent failure 
of SPLUNC1 to regulate ENaC remains to be tested.
The interactions between CFTR and ENaC are complicated and not fully understood [111, 
131, 132]. However, electrophysiological studies have revealed that ENaC is inhibited by 
cAMP/PKA in the presence of CFTR and activated by cAMP/PKC in CFTR’s absence [133, 
134]. Further support of this regulatory interaction emerged from studies with Madin Darby 
Canine Kidney (MDCK) epithelial cells where recombinant ENaC activity was decreased by 
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coexpression with full-length CFTR [135]. Similar findings emanated from a study of 
freshly prepared lung slices from wild-type vs. CFTR(−/−) mice where basal open probability 
of ENaC increased fourfold in absence of CFTR [136]. Despite these studies, how CFTR 
actually regulates ENaC remains to be determined [111].
It is also not known whether decreased CFTR expression in COPD airways leads to ENaC 
hyperactivity and emerging in vivo data suggest that ENaC activity may be intrinsically 
normal in COPD [15, 137]. Crucially, despite reduced levels of CFTR in COPD airways, the 
remaining CFTR is wild-type and not a disease-causing mutant, and it may be that the 
residual wild type CFTR activity in COPD airways (~30% of normal activity) is sufficient to 
prevent ENaC hyperactivity. The situation may change with severe COPD, however, since 
ENaC is cleaved and activated by many proteases, including neutrophil elastase and 
cathepsins [138–142]. Indeed, chronic neutrophilia is seen in severe COPD, which may 
promote cleavage and activation of ENaC due to increased neutrophil elastase levels [143].
Recent data indicate the regulation of ENaC may be abnormal in COPD. Recent data have 
indicated that extracellular ATP levels are reduced in COPD secretion, in part due to 
increased ecto-ATPase activities (Anderson, et al, Blue J. in press). Thus, ATP inhibition of 
ENaC may be reduced in COPD.
The effect of tobacco smoke on ciliary beating
Pyrolysed tobacco contains >5000 different chemicals including aldehydes, which are the 
product of combusted plant material (e.g. cellulose), heavy metals, CO and free radicals 
[144–146]. Since tobacco smoke is highly oxidized, it is very labile and its composition 
changes with time after its production [147]. Of the chemicals contained in tobacco smoke, 
acrolein, acetaldehyde, formaldehyde and Cd2+ are thought to have the biggest effect on the 
development of pulmonary disease [148]. Tobacco smoke components such as acrolein and 
acetaldehyde impair ciliary clearance [149]. Ciliary beat frequency has been shown to be 
significantly decreased in ciliated cells from nasal brushings of moderate and severe COPD 
patients compared to control and other at-risk subjects [150] and ciliary beat frequency was 
found to be lower in smoke-exposed subjects [151]. Volatile compounds in cigarette smoke 
extract are predicted to reduce ciliary beat frequency through a protein kinase C dependent 
mechanism [152]. Since these measurements were made under flooded conditions (i.e. the 
thin film ASL was washed away), this effect was likely due to changes in ultrastructure of 
the cilia rather than to changes in mucus viscosity.
Cigarette smoke (CS) exposure has been shown to impair ciliogenesis and to cause ciliary 
shortening [153]. Histone deacetylase 6, a ubiquitin ligase that also affects protein 
acetylation, has recently been implicated in ciliary shortening after CS exposure [154]. 
Specifically, CS is thought to upregulate histone deacetylase 6’s ubiquitinase activity and 
promote removal of ciliary proteins, leading to ciliary shortening. Indeed, cells with reduced 
histone deacetylase 6 expression are resistant to CS-induced ciliary shortening.
Axonemal abnormalities, including changes in the microtubule’s “9+2” arrangement, were 
also found to be about three fold greater in smokers and ex-smokers as compared to 
nonsmokers [155]. Abnormalities in radial spokes, dynein arms along with nexin links and 
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fused cilia were further observed in smokers [155–159]. Subsequent analyses revealed that 
hydrogen cyanide, formaldehyde, acrolein, acetaldehyde, ammonia, nitrogen dioxide and 
phenol all reduced ciliary beating in a similar fashion as cigarette smoke [160].
The effect of tobacco smoke on CFTR-mediated ion transport
Following both acute and chronic cigarette smoke exposure, CFTR mediated Cl− secretion 
was found to be significantly reduced in vitro and in vivo [15, 137, 161]. This inhibition was 
both rapid in onset and sustained over extended periods of time. Several mechanisms have 
been proposed to account for the reduction in CFTR activity:
i. Effects on CFTR trafficking: After tobacco smoke exposure, CFTR has been 
shown to rapidly internalize [15, 162] (Figure 1). This internalization is Ca2+ 
dependent, with the Ca2+ emanating from lysosomes rather than from the 
endoplasmic reticulum or mitochondria [163]. Recent data has implicated 
activation of the MEK-Erk1/2-MAPK pathway in this response [162]. Tobacco 
exposure also caused CFTR aggregation and induced an alteration in solubility of 
CFTR, which we speculated caused CFTR to accumulate in a perinuclear 
aggresome-like compartment rather than traffic to the lysosomes or the proteasome 
[15]. Such changes in CFTR solubility have previously been observed with 
misfolded CFTR [164–166]. Because there is a peripheral quality control system 
for surface CFTR [167, 168], it is possible that tobacco exposure induces an acute 
mis-folding of surface CFTR, leading to rapid internalization.
ii. Direct effects of tobacco smoke metabolites on CFTR function: Acrolein is a 
highly reactive tobacco smoke metabolite that is known to form covalent adducts 
with DNA [169, 170] and with proteins [171]. In single channel patch clamp 
recordings, acrolein has been demonstrated to directly affect CFTR gating [172]. 
Cigarette smoke is acidic, and 50 standard cigarettes drawn through 50 mls of Frog 
Ringer solution acidified the solution by about 2 pH units [173]. This cigarette-
exposed acidic media inhibited the activity of CFTR expressed in Xenopus laevis 
oocytes [125]. As the HCO3− secretion is also mediated by CFTR, tobacco smoke 
exposure also exhibits reduced secretion of HCO3− presumably resulting in further 
acidification of ASL [174, 175]. To date, however, there no evidence that tobacco 
exposure actually causes an acidification of the ASL in vivo.
iii. Effects of tobacco smoke and oxidative stress on CFTR expression: Tobacco 
smoke is highly oxidizing (5×1014 radicals per puff [176]). Oxidative stress is a 
well-known inhibitor of CFTR gene expression [177]. Indeed, Cd2+ and other 
oxidants present in tobacco smoke have been shown to decrease CFTR gene 
expression and to affect microRNAs, such as Mir-101 and Mir-144, that themselves 
influence CFTR expression [178]. Cd2+ was also shown to accumulate in the lungs 
of GOLD4 COPD patients and is negatively correlated with CFTR expression, 
suggesting that accumulated heavy metals in lung epithelia may act as toxins that 
continuously inhibit CFTR expression and drive mucus dehydration in severe 
COPD patients [178, 179].
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Emerging data from multiple laboratories have indicated that tobacco exposure leads to 
airway dehydration in human bronchial epithelial cells cultured at an air-liquid interface 
(Figure 1) [15, 180]. A single bout of tobacco smoke exposure (i.e. the smoke from one 
cigarette) rapidly diminished ASL height (within 30 minutes of initiation of exposure), and 
it took 3–4 hours for ASL height to return to pre-exposure levels [15]. When cultures were 
exposed to smoke chronically, resting ASL height decreased permanently, indicating a more 
severe effect of tobacco exposure on ASL homeostasis [179]. The decrease in ASL height 
was due to changes in active ion transport, as opposed to a simple drying of the ASL by the 
smoke exposure, as evidenced by studies showing that [181, 182]. pre-inhibition of ENaC 
prevented the ASL depletion caused by tobacco smoke., Furthermore, the addition of ENaC 
antagonists after tobacco-smoke induced ASL dehydration resulted in a quicker restoration 
of ASL height to normal levels, indicating that continued ENaC activity in the absence of 
CFTR function contributed to the ASL depletion [181].
The effect of tobacco smoke on mucus secretion/mucus clearance
Nasal Mucociliary clearance (MCC) has been assessed in vivo with the saccharine transit 
test. Thus, this test involves placing saccharine in the inferior nasal turbinate and measuring 
the time taken for the saccharine to be tasted, which is directly proportional to the mean 
transit of saccharin through the nasal cavity. For example, the longer it takes to taste the 
saccharine, the slower the MCC rate [183]. Nasal MCC was significantly reduced in 
smokers compare to nonsmokers as measured using this method [184].
Mucus adhesion contributes to the pathophysiology of chronic infectious airways diseases in 
different ways. The notion that mucus adhesion imparts airflow obstruction emerged from 
micro-CT studies. Specifically, Hogg et al, found that the survival rate of COPD patients 
was dominated by events internal to the airway basement membrane, i.e., epithelial 
hyperplasia and mucus obstruction [6, 36]. It has also been reported that mucus plugs from 
COPD lungs are ~7% solids [15, 185]. Our experimental data and theoretical analyses 
indicate that when mucus dehydration (as indexed by % solids) exceeds 6% solids, mucus 
clearance slows [48, 55, 186]. Indeed, the biophysical properties of 6.5% mucus became 
markedly abnormal (2 log differences) as compared to normal 2% mucus [52, 186]. These 
data predict that more concentrated mucus will be transported by cilia less effectively. In 
theory, when mucus concentrations exceed 6%, the osmotic pressure exerted by the mucins 
in the mucus layer will exceed that of the PCL, leading to a collapse of the PCL and 
adhesion of mucus to airway surfaces [55]. Mucus from CF subjects exhibited similar 
properties with elevated % solids content and subsequent mucus stasis [35, 187, 188], 
suggesting that mucus dehydration plays a role in the pathogenesis of both diseases. The 
ASL dehydration induced by tobacco-smoke mediated down-regulation of CFTR is further 
exacerbated by the concomitant increase in mucin secretion [189–191]. For example, 
acrolein increased MUC5AC expression, which contributes to an imbalance between mucin 
production and salt/water secretion [192, 193].
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Animal models of COPD
The in vivo and in vitro human data are complemented by data from animal models of 
COPD. Historically, mice, rats and ferrets have been chronically exposed to tobacco smoke 
[194–197]. For example, chronic tobacco exposure in mice causes emphysema, which has 
been attributed to macrophage elastase (MME) production. Six months of cigarette smoke 
exposure caused macrophage accumulation in murine lungs along with an enlargement of 
alveolar airspaces [198]. MME (−/−) mice were protected against this response, indicating 
that protease production is required for alveolar damage [198]. Interestingly, while mice 
develop the emphysema phenotype, they do not typically exhibit mucus obstruction/CB. 
One reason for this observation may be that reduced CFTR activity is critical for mucus 
dehydration in humans, CFTR is little expressed in murine lungs. Consistent with this 
notion, CFTR knockout mice do not exhibit a significant pulmonary phenotype [199, 200]. 
The mucociliary clearance rates observed in rodents is also slower than reported in humans, 
which may further contribute to the species differences in response to cigarette smoke [201, 
202]. Currently, and to the best of our knowledge, there are no good rodent spontaneous or 
environmentally produced models of CB dehydration.
Genetically, mucus obstruction has been induced in mice by transgenically overexpressing 
the β-subunit of ENaC, which produced a phenotype of airway surface liquid (ASL) volume 
depletion that was associated with mucus adhesion/plaque formation and the inability to 
clear inhaled bacteria that phenocopies CF and CB [203]. Importantly, these animals 
exhibited a spontaneous mortality of ~60% after 30 days that reflected mucus obstruction 
[203]. This model has helped establish the relative importance of hydration on airway 
health. In contrast, a series of mouse models with either no cilia or dysfunctional cilia 
surprisingly exhibited little or no pulmonary disease phenotype [202]. Diseases that affect 
other aspects of the innate defense mechanisms of the lung, e.g., alveolar macrophage 
dysfunction, neutrophil dysfunction, dysfunction of immunoglobulins (both secretory, IgA, 
and IgG) tend to produce disease of the alveoli rather than airways. Thus, we believe that it 
is a reasonable conclusion that mechanical (mucus) clearance is the dominant form of innate 
defense of the airways, and failure to provide this activity produces obstruction and the 
propensity for chronic infection.
Treatment for CFTR diminution and mucus dehydration in COPD
The increased awareness that CB is at least, in part, a disease of CFTR dysfunction and 
mucus dehydration, suggested that ASL/mucus rehydration would be beneficial in clearing 
airway mucus obstruction in COPD subjects. This goal may be achieved either by direct 
rehydration of the mucus with osmotic agents such as hypertonic saline or mannitol, by 
restoring CFTR function, or by inhibiting ENaC (Figure 2). The use of hypertonic saline for 
the treatment of dehydrated airways in CF patients has shown promise by improving mucus 
clearance and lung function, as well as decreasing the number of acute exacerbations (Figure 
2a) [204, 205]. Hypertonic saline has also been shown to accelerate MCC in COPD patients 
[15, 206]. In addition to increasing airway hydration, inhaled hypertonic saline treatment 
also decreased the number of neutrophils in the lung, suggesting that it may be a viable 
therapy for COPD patients [207].
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Interestingly, the duration of action of hypertonic saline is relatively short in normal and 
COPD airways as compared to CF airways [15, 204]. This short response likely reflects the 
fact that in normal airways, the high salt concentration achieved on airway surfaces 
following aerosol delivery of hypertonic saline generates chemical gradients for Cl− to be 
absorbed through CFTR and the paracellular pathway, with Na+ being absorbed through 
ENaC and also the paracellular pathway, thus limiting the sustainablilty of osmotic effects 
of hypertonic saline on airway surfaces. In contrast, the absence of CFTR function in CF 
airways eliminates the transcellular path for Cl− absorption, resulting in the maintenance of 
high concentrations of NaCl on airway surfaces. Because the high ASL Cl− concentration 
caused cannot be dissipated as rapidly, a greater, osmotically-induced hydration is generated 
[135].
The open probability of wild-type CFTR typically ranges from 0.35 to 0.40 [208, 209], and 
Po is reduced following acrolein exposure to <0.1 [172]. The G551D disease-causing CFTR 
mutation exhibits an open probability that is ~0 [210]. However, potentiator drugs such as 
VX770 (Ivacaftor/Kalydeco) have been developed which increase the open probability of 
both wild-type and G551D CFTR [211]. It has been hypothesized that such potentiators may 
be a suitable treatment to increase open probability, and hence restore Cl− secretion, in 
CFTR-deficient COPD airways (Figure 2b). Indeed, acute VX770 addition increases CFTR-
mediated Cl− secretion after cigarette smoke extract exposure in HBECs [180]. In contrast, 
while the F508 CFTR mutant is retained in the endoplasmic reticulum, it may be induced in 
vitro to traffic to the plasma membrane with a reduced open probability of ~0.1 [212]. CFTR 
correctors have also been developed that help traffic CFTR to the plasma membrane, 
although their effects on CS-exposed HBECs have not been determined [213]. As a caveat, 
it has recently been shown that chronic VX770 exposure may inhibit wild type CFTR by 
reducing CFTR’s dwell time in the plasma membrane, suggesting that VX770 may not be 
the optimal potentiator to restore CFTR function in COPD patients [214]. Thus, potentiator/
corrector based approaches to restore CFTR function are relatively new and the continued 
development of compounds designed to improve trafficking of CFTR in tobacco-
exposed/CB airways may yield novel therapeutics for the treatment of CFTR dysfunction in 
CB airways.
There are more conventional approaches to activating CFTR in COPD subjects. Since CFTR 
is a cAMP-activated channel, phosphodiesterases such as roflumilast may also serve to 
increase CFTR activation levels (Figure 2c) [182, 215]. This effect may also be present in 
COPD airways, given that ~30% of CFTR function remains [15, 137, 161]. Similarly, 
inhaled 2 adrenergic receptor agonists are a mainstay of COPD treatment, and they are 
thought to relieve the airway obstruction by inducing smooth muscle relaxation, as seen in 
asthmatic patients [216]. However, these agonists also activate CFTR [217]. To date, no 
COPD study has been completed in order to determine the most effective 2 agonist for 
activating CFTR. Such optimization of existing/FDA approved 2 agonists may provide a 
useful tool for reducing mucus dehydration in CB airways.
A fourth therapeutic approach for COPD focuses on inhibiting ENaC to restore airway 
hydration (Figure 2d). To date, no ENaC inhibitors have been used to successfully treat 
airway dehydration by limiting Na+ absorption through the airways and previous trials have 
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failed due to both safety issues and lack of efficacy [218] (amilioride trials- safe- no effect). 
Amiloride and its analogues are a series of ENaC antagonists that were initially designed to 
inhibit ENaC in the kidneys with a goal of treating hypertension [219]. Whilst efficacious at 
increasing MCC, amilioride failed therapeutically to treat CF because it was rapidly 
absorbed across the airways via organic cation transporters into the systemic circulation 
where they can gain exposure to ENaC in the kidneys [220]. Inhibition of ENaC in the distal 
convoluted tubules of the kidneys directly blocks Na+ absorption and indirectly blocks K+ 
secretion, leading to a diuresis and natriuresis that is “potassium sparing” [219]. 
Consequently, if ENaC inhibitors delivered to the lung via aerosol are absorbed systemically 
and cleared renally, hyperkalemia can result. Two inhaled ENaC antagonists (amiloride and 
GS9411) have elicited a renal response [218, 221]. Recently, novel ENaC antagonists have 
been administered by inhalation and shown to increase rehydration and ciliary beating 
without eliciting this response, suggesting that ENaC antagonism may be a viable therapy 
for ASL rehydration in COPD airways [222, 223]. Furthermore, ENaC antagonists have 
been shown to reverse ASL dehydration seen in tobacco-exposed airway epithelia, and to 
increase ciliary beat frequency in vitro, suggesting that if safety issues can be overcome, 
then ENaC antagonists may be a useful treatment for CB.
Using components of the MCC pathway as biomarkers of exposure for the 
study of new and emerging tobacco products
In addition to the existing brands of tobacco that have been well characterized (e.g. 
Marlboro, Camel cigarettes etc.), a large number “new and emerging” tobacco products and 
e-cigarettes are reaching the market that are currently unregulated by the US Food and Drug 
Administration. These products include little cigars, E-cigarettes and hookah [224]. For 
these new and emerging tobacco products, their effects on the lung are only beginning to be 
studied. It has been proposed that E-cigarettes, which produce a vapor with an electronic 
coil, may lessen the risk of developing COPD and/or lung cancer because they do not 
combust tobacco nor require pyrolysis to produce the vapor [225, 226]. Whilst the principle 
ingredients of E-cigarettes are typically propylene glycol, nicotine and flavorings, the 
chronic effect of these devices on the lungs is only beginning to be understood, and their 
propensity for triggering COPD is not known. For example, it has recently been reported 
that E-cigarette liquids promoted IL-6 production and inhibited SPLUNC1 expression [227]. 
IL-6 is known to increase mucin gene expression and secretion [228], while SPLUNC1 not 
only regulates ENaC (see above, but also plays multiple other roles in innate defense) and its 
absence could lead to altered epithelial function. Furthermore, formaldehyde has recently 
been detected in e-cigarette vapor, and this agent may be a breakdown product from the 
propylene glycol propellant [229]. As these tobacco products are newly emerging, 
appropriate human studies will need to be performed before these experiments are fully 
validated and their long term effects understood.
Chemical flavors are now widely being used in new and emerging tobacco products [230–
232]. However, while these flavors are generally safe to eat, by and large, their effects on 
the lung are unknown. Recent data have indicated that flavors such as menthol can stimulate 
transient potential receptor (TRP) channels in the airways. TRP channels are involved in 
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nociception in the airways and their stimulation reduces irritation caused by tobacco 
exposure, making menthol cigarettes easier to smoke than regular cigarettes [233]. Indeed, 
genetic variants in TRPA1 amongst the general population have been linked to an increased 
preference for menthol cigarettes and for heavier tobacco intake in a subset of the population 
[234]. Another flavor that has received attention is diacetyl, which is used in the food 
industry to provide a buttery flavor and is added to many food products, including popcorn 
and beer [235]. Diacetyl is thought to be safe when ingested orally and is approved for 
human usage [235]. However, diacetyl inhalation is known to cause bronchiolitis obliterans 
or “popcorn workers lung” [236]. Additionally, the authors reported a twofold greater risk of 
diacetyl causing COPD, although these cases may have been bronchiolitis obliterans that 
were misdiagnosed. Thus, it may wise that every flavor used in new and emerging tobacco 
products and e-cigarettes be retested for lung toxicity in order to prevent the development of 
chronic airway disease.
Considering the present shift in tobacco use from conventional cigarettes to new and 
emerging tobacco products like little cigars, smokeless tobacco and e-cigarettes, the effects 
that these new products will exert on airway hydration and associated mucociliary clearance 
are as yet untested [237–239]. Importantly, components of the mucociliary transport system 
will serve as useful biomarkers of exposure both in vivo and in vitro. In vivo, CFTR 
activity/expression, mucus clearance rates, induced sputum properties (mucus hydration, 
protease activity) are all useful and relatively accessible biomarkers that can be used to 
measure effects of exposure. Similarly, CFTR function, ciliogenesis, mucin expression and 
mucus clearance rates can all be assayed in well-differentiated HBECs in vitro following 
tobacco/e-cig exposure, suggesting that these measures will be important biomarkers that 
can be utilized to assess the relative toxicity of exposure to new and emerging tobacco 
products.
The differences between chronic bronchitis and cystic fibrosis
Although we speculate that CF and CB are characterized by relative dehydration of mucus 
and mucus adhesion, the pathophysiologic sequences that produce this state are very 
different in the two diseases. We hypothesize that the pathogenesis of CF lung disease 
directly reflects abnormal regulation of electrolyte transport to produce ASL volume 
depletion. Specifically, we speculate that the failure of CFTR function in CF airways 
produces an intrinsic defect in regulation of Na+ absorption and a failure to secrete anions 
via the tonic basal anion secretory pathway, i.e., CFTR itself. Concurrently, reduced HCO3− 
secretion due to the lack of CFTR contributes to a mildly acidic pH [127]. Thus, the primary 
defect is one of ASL volume depletion, and only later, when chronic infection sets in, does 
mucin hypersecretion commence, which worsens the relative dehydration state of mucus.
In contrast, mucus dehydration in CB is likely multifactorial. Mucin hypersecretion has been 
thought to be the primary defect in COPD that leads to relative airway surface dehydration 
[74]. Indeed, it is highly likely that high rates of secretion of mucins into the airway lumen, 
coupled with upregulated ecto-ATPase mediated reductions in extracellular ATP 
concentrations, contribute to increased mucus percent solids content. However, new data 
suggests that CFTR dysfunction contributes equally to this phenotype [11] [Anderson, Blue 
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J 2015). Compared to CF, COPD is a relatively slowly evolving disease when left untreated. 
Data from CF subjects suggest that severe CF mutations lead to a relatively complete 
inhibition of CFTR function and relatively rapid mucus plugging and heterogeneous loss of 
mucus clearance. In contrast, since tobacco exposure results in a progressive decline in 
CFTR function (50% in smokers, >70% in COPD patients), mucus dehydration is not so 
severe (~10% solids in COPD; up to 20% solids in CF) so the mucus obstruction is not so 
profound, consistent with a slower onset of disease.
Both diseases exhibit chronic inflammation. Inflammation in CF is characterized by high 
intraluminal IL 8 levels and high concentrations of polymorphonuclear cells [240]. The 
inflammatory response of the airway in COPD patients is likely more complex [241]. 
Perhaps this complexity reflects the chronic exposure to a tobacco smoke mixture that 
contains more than 5,000 chemical entities. Often, early in the disease, the inflammatory 
response is characterized by increased intraluminal and airway wall mononuclear cells, 
particularly CD4 and CD8 cells [241]. Only later in the disease, once severe obstruction of 
the airways obstruction and chronic infection sets in, does persistent neutrophilic 
accumulation in mucus become characteristic of this disease process [143]. Despite these 
differences, our knowledge of CF has helped drive a better understanding of the CFTR and 
mucus defect in COPD.
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Figure 1. Overview of airway dehydration in the pathogenesis of chronic bronchitis
A, The compromised airway hydration status leads to defective mucociliary clearance 
leading to goblet cell hyperplasia, mucus stasis and infection with subsequent manifestations 
of diseases like cystic fibrosis and chronic bronchitis. B, Exposure to tobacco smoke leads to 
relocation of surface CFTR to aggresome and release of Ca2+ from the lysosome resulting in 
augmented absorption of Na+ through ENaC and ASL height decrease.
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Figure 2. Strategies for treating airway dehydration in CB/COPD
Schema showing a typical airway epithelial cells and different therapies for ASL 
rehydration. Therapies may be inhaled or taken orally, as indicated by blue arrows. a, 
Inhaled hypertonic saline directly rehydrates the airway surface, which helps facilitate 
mucociliary clearance. b, CFTR corrector or potentiator drugs enhances CFTR channel 
activity and can be taken orally. c, cAMP mediated CFTR enhancement is achieved either 
through phosphodiesterase (PDE) inhibition or β2-adrenergic receptor (GPCR) activation. d, 
Inhaled ENaC inhibitors reduce Na+ absorption and would enhance the driving force for 
CFTR-mediated Cl− secretion.
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